Intravitreal sirolimus filed in Europe for non-infectious uveitis

Intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of non-infectious uveitis (NIU) of the posterior segment, has been filed for regulatory approval in Europe, developer Santen (Osaka, Japan) said in a press release.
The European submission is supported by data from the pivotal phase 3 SAKURA (Study Assessing double-masKed Uveitis tReAtment). The submission seeks approval to market the sirolimus, 440-ug dose for the chronic treatment of NIU of the posterior segment of the eye. By inhibiting mTOR, sirolimus interrupts a critical pathway that perpetuates the inflammatory process, controlling the disease's progression,Santen added